JP2024543413A - 結晶性イミダゾ［４，５－ｂ］ピリジン化合物、医薬組成物、及び医学的状態を治療する際のそれらの使用 - Google Patents

結晶性イミダゾ［４，５－ｂ］ピリジン化合物、医薬組成物、及び医学的状態を治療する際のそれらの使用 Download PDF

Info

Publication number
JP2024543413A
JP2024543413A JP2024527604A JP2024527604A JP2024543413A JP 2024543413 A JP2024543413 A JP 2024543413A JP 2024527604 A JP2024527604 A JP 2024527604A JP 2024527604 A JP2024527604 A JP 2024527604A JP 2024543413 A JP2024543413 A JP 2024543413A
Authority
JP
Japan
Prior art keywords
imidazo
compound
benzyl
pyrazol
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527604A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543413A5 (https=
Inventor
ロベール，ブノワ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2024543413A publication Critical patent/JP2024543413A/ja
Publication of JP2024543413A5 publication Critical patent/JP2024543413A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024527604A 2021-11-12 2022-11-11 結晶性イミダゾ［４，５－ｂ］ピリジン化合物、医薬組成物、及び医学的状態を治療する際のそれらの使用 Pending JP2024543413A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21207942.0 2021-11-12
EP21207942.0A EP4180428A1 (en) 2021-11-12 2021-11-12 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
PCT/US2022/049695 WO2023086564A1 (en) 2021-11-12 2022-11-11 Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Publications (2)

Publication Number Publication Date
JP2024543413A true JP2024543413A (ja) 2024-11-21
JP2024543413A5 JP2024543413A5 (https=) 2025-11-18

Family

ID=78617277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527604A Pending JP2024543413A (ja) 2021-11-12 2022-11-11 結晶性イミダゾ［４，５－ｂ］ピリジン化合物、医薬組成物、及び医学的状態を治療する際のそれらの使用

Country Status (10)

Country Link
US (3) US11814383B2 (https=)
EP (2) EP4180428A1 (https=)
JP (1) JP2024543413A (https=)
CN (1) CN118843624A (https=)
AU (1) AU2022387516A1 (https=)
CA (1) CA3237156A1 (https=)
IL (1) IL312625A (https=)
MX (1) MX2024005766A (https=)
TW (1) TW202334143A (https=)
WO (1) WO2023086564A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731317B (zh) * 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EP4180428A1 (en) 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
CN121464134A (zh) * 2023-05-17 2026-02-03 中枢疗法公司 咪唑并[4,5-b]吡啶化合物的颗粒、药物组合物及其在治疗医学病症中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EA201791336A1 (ru) 2014-12-18 2017-10-31 Джензим Корпорейшн Фармацевтические составы на основе ингибиторов тропомиозин-родственных киназ (trk)
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
JP7472103B2 (ja) * 2018-08-22 2024-04-22 クルゲン（シャンハイ），インク． トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法
EP4110772A4 (en) 2020-02-26 2024-04-03 Cullgen (Shanghai), Inc. TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE
EP4180428A1 (en) 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions

Also Published As

Publication number Publication date
TW202334143A (zh) 2023-09-01
US20250250274A1 (en) 2025-08-07
IL312625A (en) 2024-07-01
WO2023086564A1 (en) 2023-05-19
CN118843624A (zh) 2024-10-25
US11814383B2 (en) 2023-11-14
EP4180428A1 (en) 2023-05-17
AU2022387516A1 (en) 2024-05-23
US12291528B2 (en) 2025-05-06
EP4430043A1 (en) 2024-09-18
EP4430043A4 (en) 2025-11-05
MX2024005766A (es) 2024-07-29
US20230151008A1 (en) 2023-05-18
US20240150352A1 (en) 2024-05-09
CA3237156A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
JP7827911B2 (ja) ＭｒｇｐｒＸ２アンタゴニストおよびその使用
JP2024543413A (ja) 結晶性イミダゾ［４，５－ｂ］ピリジン化合物、医薬組成物、及び医学的状態を治療する際のそれらの使用
JP7198820B2 (ja) 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
JP7301209B2 (ja) ２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミドヘミコハク酸塩の大規模調製のためのプロセスおよび中間体、ならびに２，４，６－トリフルオロ－ｎ－［６－（１－メチル－ピペリジン－４－カルボニル）－ピリジン－２－イル］－ベンズアミド酢酸塩の調製
US20240246932A1 (en) Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
JP7787811B2 (ja) ＭｒｇｐｒＸ２アンタゴニストおよびその使用
JP2020526557A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
EP3642195A1 (en) Substituted 5-cyanoindole compounds and uses thereof
US20230087354A1 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
JP6302480B2 (ja) 中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
CN108409737B (zh) 4-甲氧基苯基取代四氢-β-咔啉哌嗪二酮类衍生物及其应用
JP2026502231A (ja) 補体因子ｂ阻害剤、その医薬組成物および使用
US10391101B2 (en) Derivatives of 7-fluoro-8-chloro-5H-dibenzo [B,E,] [1,4] diazepine and use thereof
KR100882925B1 (ko) 세로토닌 5-ｈｔ₃ａ 길항적 효과를 갖는 피라졸 유도체함유 약제 조성물
JP2002504134A (ja) 疼痛を治療するためのドラフラジン類似体の使用
US20240383892A1 (en) PARTICLES OF IMIDAZO[4,5-b]PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS
WO2009050554A2 (en) Treatment of central nervous system disorders
HK40009151A (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HK40009154A (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HK40013317B (zh) 作为janus激酶抑制剂的新的氨基-咪唑并吡啶衍生物及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251110